Ueha S. et al. reported that in subcutaneous tumor models (B16F10, Colon 26, or Lewis lung carcinoma), treatment with the anti-CD4 mAb alone demonstrated robust anti-tumor effects that exceeded those elicited by CD25 + Treg depletion or other ICI monotherapies. This evidence concerns the gene CD4 and neoplasm.